Lacosamida Generis

Lacosamide, the active ingredient in Lacosamida Generis, is a sodium channel blocker presented as an oral dosage form for oral use. It is employed as adjunctive therapy to control partial‑onset seizures in patients with epilepsy, helping to reduce seizure frequency when added to existing antiepileptic regimens.

GNH USA supplies Lacosamida Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, providing reliable access to EU‑sourced medication for clinical use. The company adheres to stringent quality standards and regulatory requirements to ensure product integrity across global markets.

Lacosamide is indicated for the treatment of focal seizure disorders and works as an adjunctive therapy in epilepsy.

Partial‑onset seizures (focal seizures): reduces seizure frequency when added to existing antiepileptic therapy. Adjunctive therapy for refractory focal epilepsy: provides additional seizure control in patients not adequately managed by other agents. Epilepsy with focal onset: helps achieve better overall seizure management as part of a combination regimen.

Lacosamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Nausea - Headache - Fatigue

Serious or Rare Side Effects: - Suicidal thoughts or behavior - Severe skin reactions such as Stevens‑Johnson syndrome - Cardiac arrhythmias including PR‑interval prolongation

When prescribing Lacosamide, clinicians should consider several precautionary measures to ensure safe use.

Renal impairment: adjust dose or monitor renal function in patients with reduced kidney function. Hepatic impairment: use with caution and consider dose adjustment in patients with liver disease. Cardiac conduction disorders: avoid in patients with known PR‑interval prolongation or arrhythmias. Pregnancy: safety data are limited; prescribe only if potential benefit justifies potential risk. Concomitant CNS depressants: monitor for enhanced sedation or respiratory depression. Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Lacosamide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lacosamide plasma concentrations. - Other sodium‑channel blocking antiepileptics (e.g., carbamazepine, phenytoin): can potentiate cardiac conduction effects. - Concomitant use with drugs that prolong PR interval (e.g., diltiazem, verapamil): risk of significant cardiac rhythm disturbances.

Moderate Interactions (Monitor Closely): - Alcohol or other central nervous system depressants: may enhance sedation and dizziness. - Diuretics that alter electrolyte balance: monitor serum electrolytes as changes can affect seizure threshold. - Antacids or high‑dose calcium supplements: may modestly reduce oral absorption of lacosamide.